Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PrefMab: Patient Preference for SC vs IV Rituximab in CD20+ NHL
NCT01724021Phase 3Completed
- Sponsor
- Roche
- Start
- Dec 2012
- Primary completion
- Jan 2015
- Modality
- Monoclonal Antibodies
- Countries
- 32
01
Overview
A Phase 3 trial of rituximab in diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), sponsored by Roche. Started Dec 2012; status: completed.
02
Drugs
rituximab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT01724021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01724021.